Vyjuvek™ (beremagene geperpavec-svdt)

Vyjuvek (beremagene geperpavec‑svdt) is covered for topical treatment of wounds in patients ≥6 months with dystrophic epidermolysis bullosa who have a confirmed pathogenic COL7A1 mutation, at least one clinical feature and one or more open wounds; patients <6 months, without genetic confirmation of COL7A1 mutation, or without open wounds are not eligible. Approval is for 6 months and requires prescription/consultation by a dermatologist or wound‑care specialist experienced in DEB, documentation of genetic testing, age, clinical features and wounds, and once‑weekly topical dosing with age‑based maximums (6 months–<3 years: 1.6×10^9 PFU/0.8 mL weekly; ≥3 years: 3.2×10^9 PFU/1.6 mL weekly).

"The individual must meet all of the following criteria for approval:"

Sign up to see full coverage criteria, indications, and limitations.